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Objective To determine the frequency and clinical-
radiological associations of antibodies to myelin
oligodendrocyte glycoprotein (MOG) and aquaporin-4
(AQP4) in children presenting with neuromyelitis optica
(NMO) and limited forms.
Methods Children with a first event of NMO, recurrent
(RON), bilateral ON (BON), longitudinally extensive
transverse myelitis (LETM) or brainstem syndrome (BS)
with a clinical follow-up of more than 12 months were
enrolled. Serum samples were tested for MOG- and
AQP4-antibodies using live cell-based assays.
Results 45 children with NMO (n=12), LETM (n=14),
BON (n=6), RON (n=12) and BS (n=1) were included.
25/45 (56%) children had MOG-antibodies at initial
presentation (7 NMO, 4 BON, 8 ON, 6 LETM). 5/45
(11%) children showed AQP4-antibodies (3 NMO, 1
LETM, 1 BS) and 15/45 (33%) were seronegative for
both antibodies (2 NMO, 2 BON, 4 RON, 7 LETM). No
differences were found in the age at presentation, sex
ratio, frequency of oligoclonal bands or median EDSS at
last follow-up between the three groups. Children with
MOG-antibodies more frequently (1) had a monophasic
course (p=0.018) after one year, (2) presented with
simultaneous ON and LETM (p=0.004) and (3) were less
likely to receive immunosuppressive therapies
(p=0.0002). MRI in MOG-antibody positive patients (4)
less frequently demonstrated periependymal lesions
(p=0.001), (5) more often were unspecific (p=0.004)
and (6) resolved more frequently (p=0.016).
Conclusions 67% of all children presenting with NMO
or limited forms tested positive for MOG- or AQP4-
antibodies. MOG-antibody positivity was associated with
distinct features. We therefore recommend to measure
both antibodies in children with demyelinating
syndromes.
INTRODUCTION
Neuromyelitis optica (NMO) is characterised by
episodes of recurrent unilateral or bilateral optic
neuritis (BON) and transverse myelitis (TM).1
Further diagnostic criteria are the presence of a
spinal cord lesion extending over three or more
vertebral segments on MRI, a brain MRI that does
not meet the criteria for multiple sclerosis (MS)
and the presence of serum aquaporin-4 (AQP4)
antibodies. Atypical clinical manifestations such as
brainstem syndromes (BS) have been observed in
adults and children with AQP4 antibodies, and are
included under the umbrella term: NMO spectrum
disorders (NMOSD).2 3 In sera of adult patients
with NMOSD, AQP4 antibodies are found in up to
80% of cases and are associated with future
relapses or even linked with the conversion to
NMO.4–8 Nevertheless, a subgroup of patients, par-
ticularly children with NMO or limited forms such
as BON thought to be associated with a subsequent
development of NMO, have no detectable AQP4
antibodies. Several studies recently showed that
patients with AQP4 antibody seronegative NMO or
relapsing optic neuritis (RON) present with anti-
bodies against the myelin oligodendrocyte glyco-
protein (MOG). Presence of these antibodies was
associated with younger age at presentation, fewer
relapses and better outcome.9–14 MOG antibodies
—predominantly of IgG1 isotype—are directed
against multiple, extracellular conformational epi-
topes of MOG on the outmost surface of the
myelin sheath, induce complement-mediated cyto-
toxicity in vitro15 and appear to transiently disrupt
oligodendrocytic microtubule organisation.16 17 We
report the frequency of serum IgG MOG and
AQP4 antibodies in children with a first inflamma-
tory, demyelinating event with symptoms poten-
tially indicative of NMO or limited forms of the




Children referred to our attention with suspected
acute inflammatory demyelinating episodes from
12 university hospitals and 8 large community hos-
pitals in Austria, Canada, Germany, Italy and
Switzerland, were tested for serum MOG and
AQP4 antibodies, and subsequently included in an
ongoing prospective study.
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From this prospectively followed cohort with a total of 295
patients including children with acute disseminated encephalo-
myelitis (ADEM), clinical isolated syndromes (eg, ON) or MS,
48 children with the following criteria were selected: (1) initial
diagnosis of NMO or limited forms such as isolated longitudin-
ally extensive TM (LETM), BON, BS, recurrent optic neuritis
(RON) (2) combined with an MRI non-diagnostic for MS, (3)
age of the patient <18 years at time of inclusion, (4) a follow-up
interval of at least 12 months and (5) exclusion of alternative
diagnoses. Five previously published patients were included as
new follow-up information including clinical, imaging and anti-
body status was obtained.13 14 Three patients were finally diag-
nosed with an alternative diagnosis and excluded (mitochondrial
encephalomyopathy, lactic acidosis, and stroke-like episodes
(n=1), MS (n=2) (figure 1).
Diagnosis of NMO was made according to Wingerchuk et al2
revised diagnostic criteria, requiring ON and acute myelitis,
either simultaneously or subsequently, and two of three support-
ive criteria (LETM, non-MS-like cerebral MRI, AQP4 antibody
seropositivity).
Clinical details of the first event were obtained, with a case
report form sent to all referring physicians. Clinical follow-up
information including neurological symptoms and other seque-
lae (eg, epilepsy) was obtained via medical reports or a standar-
dised questionnaire filled out by the referring physicians every
6–12 months or at relapses. The Expanded Disability Status
Scale (EDSS) scoring system was used to estimate the disability
at onset and the clinical outcome.18
Antibody assays
All serum samples were analysed for the presence of IgG anti-
bodies to MOG and AQP4 by recombinant live cell-based
immunofluorescent assays with HEK293A cells, as previously
described.15 19 Initial samples were obtained before anti-
inflammatory therapy with steroids was started, in the majority
of cases. Screening was performed at dilutions of 1:20 and 1:40
by at least two independent clinically blinded investigators (MR
and KS), and antibody titres of positive serum samples were
determine by serial dilutions. MOG antibody titre levels of
≥1:160 were classified as seropositive, as previously described.19
Serum follow-up samples were available from 28/30 children
with MOG or AQP4 antibodies.
Neuroimaging
MRI studies from 44/45 children were sent for further evalu-
ation (MB and KR). Only written MRI reports were available in
one case with RON. Forty-two of 44 children had a spinal and
cerebral MRI. In 38/44 children, MRI was performed on scan-
ners with a field strength of 1.5 T, in 4/44 with 1.5 and 3.0 T
scanners, and in 2/44, with 3.0 T scanners. MRI studies were
assessed including the following sequences: T2 axial,
fluid-attenuated inversion recovery axial, T2 sagittal, T1 axial
with contrast medium, spinal cord T2 sagittal and T1 sagittal
with contrast medium. MRI follow-up studies were available
from 28/45 children and compared in the same fashion as the
initial MRIs. In order to compare the initial with the follow-up
MRI results, the findings were categorised into four subgroups:
complete resolution, mild residuals (few remaining T2 signal
changes, but much improved), moderate residuals (only minor
improvement of T2 signal changes) and severe residuals (eg,
atrophy).
Statistical analysis
Statistical analysis was performed using IBM SPSS, release V.22.0
(IBM Corporation). We compared clinical, demographic, neuror-
adiological and serological data using the Kruskal-Wallis test and
χ2 test. Corrected Fisher’s exact contingency table analysis was
calculated using an online calculator (http://www.physics.csbsju.
edu/stats/exact_NROW_NCOLUMN_form.html). Statistical sig-
nificance was defined as a two-sided p value of <0.05.
RESULTS
Clinical characteristics of children with NMO and limited
forms
Forty-five children were included in the study (23 female/22
male) with a median age at initial presentation of 9 years (range:
Figure 1 Flow chart study profile
(AC, acute cerebellitis; ADEM, acute
demyelinating encephalomyelitis; ADS,
acquired demyelinating syndromes;
AQP4, aquaporin-4; BON, bilateral
optic neuritis; BS, brainstem syndrome;
CIS, clinical isolated syndrome; FU,
follow-up; LETM, longitudinally
extensive transverse myelitis; MOG,
myelin oligodendrocyte glycoprotein;
MS, multiple sclerosis; NMO,
neuromyelitis optica; OIND, other
inflammatory neurological disease; ON,
optic neuritis; OND, other neurological
disease; pos, positive; RON, recurrent
optic neuritis.
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0.75–17 years). The majority of children were Caucasian
(n=41/45). Only four children were non-Caucasian (2 Arabs,
1 Pakistani, 1 Tamilian).
At baseline, six children had NMO, 16 LETM, 8 BON and
3 presented with symptoms suggestive of a BS. Twelve chil-
dren who had initially presented with unilateral ON devel-
oped further episodes of ON (n=11) or LETM (n=1), and
were retrospectively included and assigned the diagnosis,
recurrent ON (RON or NMO (figure 2 and table 1).
Cerebrospinal fluid (CSF) studies showed that 24 of 45 (53%)
children had a CSF pleocytosis (>4 cells/mL). Six of 45
children had oligoclonal bands (OCBs) in CSF. Forty-four of
45 (98%) children were treated with intravenous methylpred-
nisolone (20 mg/kg/day for 3–5 days). Seven of 44 (16%) chil-
dren received two or more courses of IVMP. Six of 44 (13%)
children were treated additionally with intravenous immuno-
globulin. Four of 45 (9%) children also had plasma exchange
therapy. One child was exclusively treated with a one-time
prednisolone bolus.
All children had a follow-up of at least 12 months. Median
overall follow-up of all children was 33 months (range: 12–
113 months). During the first 12 months, 17/45 children had
further demyelinating episodes and were either assigned the
diagnosis RON (n=8) or NMO (n=4), or maintained their
initial diagnoses (n=5). Four of eight children with RON had
additional relapses after 12 months (see eTable 1).
Another 7/45 children had further demyelinating episodes
more than 12 months later and were diagnosed subsequently
with NMO (n=2) or RON (n=4) (see eTable 1). One
seronegative patient with LETM had two further episodes of
LETM (see figure 2 and see eTable 1).
More than half of the children (26/45) showed a good recov-
ery with an EDSS of 0 at final follow-up. Nine of 45 patients
had various degrees of visual impairment ranging from a visual
acuity (VA) between 0.6 and 0.8 (n=8) or <0.6 (n=1). Nine of
45 children had a range of neurological sequelae such as brisk
reflexes (n=2), bladder dysfunction (n=3), abducens nerve palsy
(n=1), monoplegia (n=1) or respiratory insufficiency (n=2).
One patient with respiratory insufficiency died (pat. 39, see
eTables 1 and 2). Another patient (pat. 40) had severe bilateral
visual loss and a paraparesis.
Very recently, new international consensus diagnostic criteria
for NMOSD were published.20 We applied these criteria retro-
spectively on our study group (see eTable 3) with the relevant
finding that all AQP4 antibody-positive patients could be diag-
nosed as NMOSD with AQP4 antibodies. The other nine NMO
patients (7 with MOG antibodies, 2 without MOG or AQP4
antibodies) fulfilled criteria for NMOSD without AQP4 anti-
bodies. The remaining patients (6 BON, 12 RON, 13 LETM)
could not be diagnosed as NMOSD using the new criteria.
Serum MOG and AQP4 antibody status at initial clinical
presentation and follow-up
Twenty-five (55%) of 45 children (13 female/12 male) with
NMO (n=6), ON (n=7), BON (n=5) or LETM (n=7), had a
median titre of serum MOG antibodies of 1:1280 (range:
1:160–1:5120). Follow-up serum samples from different time
points (range: 1–86 months) were available from 23/25
Figure 2 Diagnoses at baseline, after 1 year and after more than 1 year (AQP4, aquaporin-4; BON, bilateral optic neuritis; BS, brainstem
syndrome; LETM, longitudinally extensive transverse myelitis; MOG, myelin oligodendrocyte glycoprotein; NMO, neuromyelitis optica; ON, optic
neuritis; pos, positive; RON, recurrent optic neuritis.
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Table 1 Comparison of demographic data, clinical features and outcome of 45 children with NMO or limited forms of the disease with
MOG-IgG, AQP4-IgG or absent antibodies
MOG-IgG positive (n=25) AQP4-IgG positive (n=5) Seronegative (n=15) p Value
At baseline
BL MOG-IgG 25 (100.0%) 0 (0.0%) 0 (0.0%)
Titre 1280 (160–5120)* 0 (0–20) 0 (0–40)
BL AQP4-IgG 0 (0.0%) 5 (100.0%) 0 (0.0%)
Titre 0 (0) 320 (20–5120)* 0 (0)
Females 13 (52.0%) 4 (80.0%) 6 (40.0%) 0.298†
Age at onset (y) 7 (2–15)* 12 (6–14)* 11 (1–17)* 0.193*
Clinical FU (mo) 33 (12–112)* 27 (12–68)* 40 (12–113)* 0.604*
Serological FU (mo) 20 (1–86)* 16 (8–47)* 25 (3–33)* 0.990*
EDSS at BL 5 (2–8.5)* 4 (3–6.5)* 4 (2–9)* 0.803*
Initial diagnosis
NMO 6 (24.0%) 0 (0.0%) 0 (0.0%) 0.004‡
Unilateral ON 7 (28.0%) 0 (0.0%) 5 (33.3%)
BON 5 (20.0%) 1 (20.0%) 2 (13.3%)
LETM 7 (28.0%) 1 (20.0%) 8 (53.3%)
BS 0 (0.0%) 3 (60.0%) 0 (0.0%)







CSF OCB 2 (8.0%) 2 (40.0%) 2/14 (14.3%) 0.163†
CSF cells >4/mL 13 (52.0%) 5 (100.0%) 6/14 (42.9%) 0.082†
CSF cell count/mL 17 (0–331)* 28 (10–100)* 2 (0–90)* 0.108*
After 12 months
NMO 7 (28.0%) 2 (40.0%) 1 (6.7%) 0.010‡
Mono ON 1 (4.0%) 0 (0.0%) 4 (26.7%)
BON 4 (16.0%) 0 (0.0%) 2 (13.3%)
RON 7 (28.0%) 0 (0.0%) 1 (6.7%)
LETM 6 (24.0%) 1 (20.0%) 7 (46.7%)
BS 0 (0.0%) 2 (40.0%) 0 (0.0%)
Monophasic 1 year 14 (56.0%) 1 (20.0%) 13 (86.7%) 0.018†
Relapses 1 year 1 (1–4)* 2 (1–4)* 1 (1–3)* 0.027*
At last follow-up
FU MOG-IgG 17/23 (74%) 0/5 (0.0%) 0/6 (0.0%)
Titre 160 (40–2560)* 0 (0) 0 (0–80)
FU AQP4-IgG 0/23 (0.0%) 4/5 (80.0%) 0/6 (0.0%)
Titre 0 (0) 80 (0–5120)* 0
EDSS at last FU 0 (0–6)* 1 (0–4)* 1 (0–7)* 0.146*
No ON ever 6 (24.0%) 2 (40.0%) 7 (46.7%) 0.402†
Unilateral ON ever 9 (36.0%) 2 (40.0%) 6 (40.0%)
BON ever 10 (40.0%) 1 (20.0%) 2 (13.3%)
Myelitis ever 13 (52.0%) 4 (80.0%) 9 (60.0%) 0.500†
LETM ever 13 (52.0%) 3 (60.0%) 9 (60.0%) 0.866†
Brainstem ever 1 (4.0%) 3 (60.0%) 1 (6.7%) 0.001†
Final diagnosis
NMO 7 (28.0%) 3 (60.0%) 2 (13.3%) 0.169‡
BON 4 (16.0%) 0 (0.0%) 2 (13.3%)
RON 8 (32.0%) 0 (0.0%) 4 (26.7%)
LETM 6 (24.0%) 1 (20.0%) 7 (46.7%)
BS 0 (0.0%) 1 (20.0%) 0 (0.0%)
NMO
Simultaneous 6 (85.7%) 0 (0.0%) 0 (0.0%) 0.015‡
Sequential 1 (14.3%) 3 (100.0%) 2 (100.0%)
Systems affected
NMO 7 (28.0%) 3 (60.0%) 2 (13.3%) 0.042‡
Isolated ON 12 (48.0%) 0 (0.0%) 6 (40.0%)
Isolated LETM 6 (24.0%) 1 (20.0%) 7 (46.2%)
Isolated brainstem 0 (0%) 1 (20.0%) 0 (0.0%)
Monophasic 13 (52.0%) 0 (0.0%) 8 (53.3%) 0.095‡
Relapses 1 (1–5)* 2 (2–4)* 1 (1–3)* 0.107*
Continued
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children, revealing that 17 children were still seropositive
for MOG antibodies with a median titre of 1:160 (range:
1:40–1:2560) after median serological follow-up of 20 months
(table 1).
Five (9%) of 45 patients with LETM, BON or BS (n=3) had
detectable serum AQP4 antibodies (median titre: 1:320; range:
1:20–1:5120). Four of five AQP4 antibody seropositive patients
still showed antibodies after a median serological follow-up of
16 months (range: 9–47), with a median titre of 1:80 (range: 0–
1:5120).
Fifteen (33%) of 45 children had neither MOG nor AQP4
antibodies at initial presentation. From six children, follow-up
samples (median 25 months; range: 3–33) were available and
remained negative for serum MOG and AQP4 antibodies.
Neuroimaging features at disease onset and follow-up of
children with MOG, AQP4 or with absent antibodies
Cerebral MRI was performed in all patients at initial presenta-
tion. Thirty-nine of 45 children also underwent a spinal MRI
(table 2).
All characteristic MRI findings of NMO, such as medullary
lesions (figure 3A), hypothalamic and periaqueductal lesions
(figure 3B), LETM (figure 3C), ON (figure 3D), area postrema
and corpus callosum lesions (figure 3E), and unspecific periven-
tricular lesions (figure 3F), were found in the five AQP4
antibody-positive patients, although in one patient, not all types
of lesions were found. The lesions appeared sequentially (figure
3A–D), or were detected only partially (figure 3E–H). Also, in
MOG antibody-positive patients, typical lesions for NMOSD,
such as periependymal lesions or rostral extending LETM, were
found (figure 3I–K). All patients with an acute myelitis showed
lesions extending over three vertebral segments (LETM). LETM
was detected in 1/5 AQP4 antibody-positive (figure 3G), 13/25
MOG antibody-positive (figure 3K) and in 8/15 seronegative
patients at baseline (table 2). Lesions spanned more than 10 ver-
tebral segments in 1/1 AQP4 antibody-positive, in seven (54%)
of 13 MOG antibody-positive and in five (63%) of eight sero-
negative patients. Rostral extension of cervical lesions into the
medulla oblongata was found in 3/13 MOG antibody-positive
(figure 3K) and in none of the AQP4 antibody-positive patients.
Involvement of the conus was found in 5/13 MOG antibody-
positive patients, 4/8 seronegative patients, and not in the AQP4
antibody-positive patient with LETM at baseline. One AQP4
antibody-positive patient, who initially had no spinal lesion but
subsequently developed a LETM, also showed involvement of
the conus (pat. 27).
Characteristic lesions around the third ventricle, the aqueduct,
or adjacent to the fourth ventricle, were found only in 3/5 AQP4
antibody-positive (figure 3B), 2/25 MOG antibody-positive
children (figure 3I, J), and in none of the seronegative children.
Small and well-defined lesions were found in 3/5 AQP4
antibody-positive (figure 3F, H), 1/25 MOG antibody-positive
Table 1 Continued
MOG-IgG positive (n=25) AQP4-IgG positive (n=5) Seronegative (n=15) p Value
Recovery
Complete 17 (68.0%) 3 (60.0%) 6/14 (42.8%) 0.478‡
Minor residuals 7 (28.0%) 2 (40.0%) 6/14 (42.8%)
Severe residuals 1 (4.0%) 0 (0.0%) 2/14 (14.3%)
No therapy 16 (64.0%) 0 (0.0%) 13 (86.7%) 0.0002‡
Immunosuppression 3 (12.0%) 5 (100.0%) 2 (13.3%)
Immunomodulation 6 (24.0%) 0 (0.0%) 0 (0.0%)







*Median (range), Kruskal-Wallis test.
†χ2 test.
‡Corrected Fisher’s exact contingency table analysis.
AQP4, aquaporin-4; BL, baseline; BON, bilateral optic neuritis; BS, brainstem syndrome; CSF, cerebrospinal fluid; EDSS, Expanded Disability Status Scale; FU, follow-up; LETM,
longitudinally extensive transverse myelitis; MOG, myelin oligodendrocyte glycoprotein; NMO, neuromyelitis optica; OCB, oligoclonal band; ON, optic neuritis; RON, recurrent optic
neuritis.
Table 2 Comparison of MRI of 45 children with NMO or limited










Normal MRI 6 (24.0%) 0 (0.0%) 5 (33.3%) 0.012*
ON 3 (12.0%) 1 (20.0%) 1 (6.7%)
LETM 5 (20.0%) 1 (20.0%) 7 (46.7%)
NMO like 1 (4.0%) 3 (60.0%) 0 (0.0%)
Unspecific lesions 1 (4.0%) 0 (0.0%) 1 (6.7%)
Blurred+ON or
LETM
9 (36.0%) 0 (0.0%) 1 (6.7%)
MRI-ON 6 (24.0%) 1 (20.0%) 1 (6.7%) 0.378*
MRI-LETM 13 (52.0%) 1 (20.0%) 8 (53.3%) 0.390*
Periependymal 2 (8.0%) 3 (60.0%) 0 (0.0%) 0.001*
Blurred lesions 9 (36.0%) 0 (0.0%) 1 (6.7%) 0.043*
Unspecific lesions 1 (4.0%) 3 (60.0%) 2 (13.3%) 0.004*
MRI at follow-up
MRI follow-up
BL+FU normal 4/15 (26.7%) 0/4 (0.0%) 4/9 (44.4%) 0.246‡
FU normal 6/15 (40.0%) 1/4 (25.0%) 2/9 (22.2%)
Mild residuals 5/15 (33.3%) 1/4 (25.0%) 2/9 (22.2%)
Moderate
residuals
0/15 (0.0%) 1/4 (25.0%) 0/9 (0.0%)
Severe residuals 0/15 (0.0%) 1/4 (25.0%) 1/9 (11.1%)
Moderate/severe
MRI residuals
0/15 (0.0%) 2/4 (50.0%) 1/9 (11.1%) 0.018‡
*χ2 test.
†Median (range), Kruskal-Wallis test.
‡Corrected Fisher’s exact contingency table analysis.
AQP4, aquaporin-4; BL, baseline; FU, follow-up; LETM, longitudinally extensive
transverse myelitis; MOG, myelin oligodendrocyte glycoprotein; NMO, neuromyelitis
optica; ON, optic neuritis.
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and 2/15 seronegative patients. Blurred, hazy and large
(ADEM-like) lesions in supratentorial white matter, basal
ganglia, thalamus, or brainstem, were not present in AQP4 anti-
body positive, but were seen in 9/25 of the MOG antibody-
positive (figure 3L) and, rarely, in seronegative children (n=1).
In MOG antibody-positive patients, blurred lesions were com-
bined with LETM in 7/9 and with ON in 2/9 patients.
MRI follow-up at least 1 month after the first event was avail-
able for 4/5 AQP4 antibody-positive, 15/25 MOG antibody-
positive and 9/15 seronegative patients. Residual findings were
grouped as mild, moderate or severe.
Spinal MRI follow-up showed that the AQP4 antibody-
positive patient with LETM at initial presentation still had
severe residual lesions 5 months later. In the MOG antibody-
positive patients with LETM, MRI follow-up revealed a com-
plete resolution of the lesions in 6/8 patients and minor resi-
duals in 2/8. Three of four seronegative patients had a complete
resolution of the LETM and one child still had severe residual
lesions (table 2).
Brainstem lesions around the third ventricle, aqueduct, or
fourth ventricle, resolved in all AQP4 and MOG antibody-
positive patients with a MRI follow-up (n=4). Supratentorial
lesions almost completely resolved in all MOG antibody-
positive patients (n=6), while only 2/4 AQP4 antibody-positive
patients had complete resolution of parenchymal lesions
(table 2).
Comparison of clinical and radiological features of MOG,
AQP4 positive and seronegative children
At initial manifestation, children with AQP4 antibodies were
slightly older, although not statistically significantly, than MOG
antibody-positive or seronegative patients (table 1). Also, no dif-
ferences were found between the three groups with regard to
the frequency of OCBs, number of CSF cells, male to female
Figure 3 MRI of children with neuromyelitis optica (NMO) and related disorders. (A–D) Imaging of a 12-year-old girl (pat. 27, see eTables 1 and
2) with aquaporin-4 (AQP4) antibody-positive NMO, who presented with vomiting, lower cranial nerve dysfunction, paraesthesia of the arms and
legs and paraparesis. The initial MRI (A, sagittal T2) revealed a medullary lesion (arrowhead). Three months later, hypothalamic and periaqueductal
lesions appeared (B, axial fluid-attenuated inversion recovery (FLAIR)), 4 months later a longitudinally extensive transverse myelitis (LETM) was noted
(C, sagittal T2), and 7 months later an optic neuritis was seen (D, coronar T2). (E and F) The cerebral MRI of a 14-year-old boy (pat. 28) with AQP4
antibody-positive NMOSD, who presented with left facial sensory and motor deficit, vomiting and singultus, showed lesions in the area postrema
(arrowhead) and corpus callosum (double arrowhead) (E, sagittal T2), and an unspecific periventricular lesion (arrowhead) (F, coronar-FLAIR). (G and
H) MRI of a 13-year-old girl (pat. 29) with AQP4 antibody-positive LETM, who presented with paraparesis and bladder dysfunction, showed an
LETM extending over more than 10 segments (G, sagittal T2), and unspecific right parietal lesions (arrowhead) (H, axial-FLAIR). (I and J) MRI of a
4-year-old boy (pat. 8) with myelin oligodendrocyte glycoprotein (MOG) antibody-positive LETM, who presented with paraparesis and dysesthesia,
revealed in addition to the LETM lesions around the third (I) and fourth ventricle (arrowheads) ( J, both axial-FLAIR). (K and L) MRI of a 5-year-old
boy (pat. 6) with MOG antibody-positive LETM, who presented with weakness and pain in the lower limbs, and bowel and bladder dysfunction,
showed a LETM extending rostral into the medulla (K, sagittal T2) and blurred supratentorial lesions (L, axial T2).
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ratio, EDSS at follow-up evaluation, or severity of visual loss at
initial presentation or at recovery (table 1).
Depending on the antibody studies, however, the following
important differences between the three groups of children
were noted (table 1): (1) Children with involvement of the optic
nerve including NMO, BON and unilateral ON with subsequent
recurrent attacks of ON were more likely to have MOG than to
have AQP4 or absent antibodies. (2) None of the five children
with AQP4 antibodies presented with simultaneous ON and
TM. (3) All children presenting with sole symptoms suggestive
of a BS had AQP4 antibodies. (4) Children with AQP4 anti-
bodies were less likely to have a monophasic course, had more
demyelinating episodes after 1 year and were treated more often
with immunosuppressive/immunomodulating therapies. (5) MRI
at baseline of children with MOG antibodies was much more
likely to show (1) a normal cerebral MRI or (2) an ADEM-like
pattern with hazy, blurry, widespread lesions in the context of
limited forms of the disease and (3) a significantly better reso-
lution of MRI signal changes, compared to children with AQP4
seropositive NMOSD.
DISCUSSION
We report the frequency of serum MOG and AQP4 antibodies
in 45 children with NMO or with limited forms of the disease.
More than half of all children including those presenting with
an NMO phenotype had serum MOG antibodies, while AQP4
antibodies were only detected in a small subgroup of children,
all of whom presented initially with only a single clinical core
feature of NMOSD.
MOG antibodies have been recently reported in a variety of
paediatric demyelinating disease phenotypes including children
with ADEM and recurrent ON, and in a group of young
patients with ADEM-like onset followed by monophasic or
recurrent ON (ADEM-ON).14 21 22 MOG seropositivity has
also been reported in a subset of adults and children with AQP4
antibody seronegative NMO and NMOSD.10–13 Reported fre-
quencies of positive MOG antibodies in adult cohorts of
patients with NMOSD vary between 7.4% and 39%, which is
most likely also influenced by different MOG antibody assays
and referral bias.11 12 Taken together, these studies indicate that
patients with NMOSD with MOG antibodies have fewer
attacks, BON and more caudal myelitis, and tend to better
recover than patients with AQP4 antibodies and those who were
seronegative for both antibodies.11 23 In our cohort, children
with MOG antibodies were also less likely to have relapses, less
often treated with immunosuppressive or immunomodulating
therapies and less likely to have residual lesions on MRI
follow-up studies.
In the past, MOG antibodies have been thought to be asso-
ciated with the pathological events leading to MS. However,
two studies have shown that MOG antibodies are nearly exclu-
sively found in children with monophasic or relapsing events
other than MS.24 25 Ketelslegers et al found only one of 47 chil-
dren who were finally diagnosed with MS as having MOG anti-
bodies at initial presentation, pleading strongly against a MS
diagnosis in children with acquired demyelinating syndromes
and positive MOG antibodies.25
Two-thirds of all children with MOG antibodies had involve-
ment of the optic nerves in our cohort, suggesting that the optic
nerves are prime targets in the disease process for reasons that
are not entirely resolved. MOG antibodies were also detected in
children with LETM, which is in contrast to adults with LETM,
who show higher frequencies of AQP4 antibodies in addition to
a higher relapse rate and a high risk for sequential NMO.26 In
our cohort, the majority of children with LETM and MOG anti-
bodies (5/7) had a single episode and no further relapses such as
ON or LETM after a median follow-up of 30 months. Only one
child with LETM and MOG antibodies had a second episode of
LETM and another MOG antibody-positive patient with LETM
had a subsequent episode of ON and was thus diagnosed as
NMO (see eTable 1). MRI findings in children with AQP4 anti-
bodies and NMOSD in contrast to children with MOG anti-
bodies have recently been reported in more detail. Children
with NMOSD and AQP4 antibodies, similarly to adults, have
lesions that follow the distribution of AQP4-rich areas in the
brain.27–29 Brain lesions are primarily found in the periventricu-
lar region of the third ventricle, in the periaqueductal grey
matter and in the dorsal brainstem adjacent to the fourth ven-
tricle. In our series, all AQP4 antibody-positive patients had a
range of signal changes including the characteristic lesions
around the third ventricle and fourth ventricle or aqueduct.
However, two children with MOG antibodies and LETM also
had periependymal lesions near the third and fourth ventricle,
indistinguishable from AQP4 antibody-positive NMO. A recent
study of adult patients with NMOSD also found that lesions
adjacent to the fourth ventricle were common in MOG
antibody-positive patients.23
LETM is the most specific radiological finding supporting the
diagnosis of NMO in adults and usually prompts the clinician
to test for AQP4 antibodies. In children, however, LETM
appears to be less specific and can also be found in ADEM or
MS.30 31 In our cohort, LETM was found in all three patient
groups with some important associated features in children with
MOG antibodies, such as widespread and rostral extension into
the medulla in addition to blurred, hazy and widespread lesions
reminiscent of ADEM. This pattern of blurred, hazy and wide-
spread lesions also affecting the spinal cord was recently
described in children with ADEM and high titre MOG anti-
bodies.31 The spinal lesions in MOG antibody-positive patients
did not involve the conus more frequently, unlike in adult
cases.11 23 As in MOG antibody-positive ADEM, the MRI
lesions in children with NMO phenotype and MOG antibodies
resolved whereas AQP4 antibody-positive patients still showed
major signal alterations on follow-up studies.
Our findings in children with an NMO phenotype, MOG
antibodies and an ADEM-like MRI underscore the point that
MOG antibody-positive demyelinating diseases are not separate
disease entities. More likely they represent a continuum with
overlapping features including children with BON and LETM,
and should be classified in the future under the umbrella MOG
antibody-positive diseases. This is in line with a recent paper by
Zamvil and Slavin,32 who also suggested that MOG-positive
NMO phenotype should not be included under the term
NMOSD.
In our study, we focused on children presenting with NMO
and limited forms, and the respective antibody status, and found
that MOG antibodies are present in a substantial number of
patients. In order to better define the whole spectrum of
MOG-positive disease manifestations, one possibility would
have been to include all children with an acute demyelinating
event and positive MOG antibodies, which will be the focus of
an ongoing research project.
Very recently, an international panel of experts published new
consensus guidelines for adults and children with NMOSD. The
new guidelines appreciate the wider spectrum of symptoms in
the context of AQP4 antibody positivity, and demand more
stringent clinical and MRI criteria for patients who are AQP4
antibody negative.20
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We retrospectively analysed our clinical data and found that
all our children with AQP4 antibodies fulfilled the criteria for
NMOSD (see eTable 3). In addition, MOG antibody-positive
children with the core symptoms of ON and TM with LETM
also fulfilled the additional MRI criteria recommended by the
new guidelines and can therefore be grouped as NMOSD
without AQP4 antibodies. The new guidelines also appreciate
that limited forms such as BON appear to have a higher risk of
subsequent demyelinating episodes other than MS and that the
presence of LETM in children is not pathognomonic for
NMOSD.
We believe that, particularly in children with NMOSD and
limited forms such as sole BON or LETM, a larger proportion
than previously thought have other autoantibodies including
MOG antibodies and that in the future the antibody status
should be considered for the clinical diagnosis.
CONCLUSIONS
As more than half of the included children had MOG anti-
bodies, we recommend MOG antibody testing in patients with
suspected NMOSD. As case numbers are small due to the rarity
of these disorders in paediatric patients, further collaborative
studies, especially regarding outcome, relapse rate and the
appropriate treatment, are needed.
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